Camurus Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Camurus hat ein Gesamteigenkapital von SEK2.6B und eine Gesamtverschuldung von SEK0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen SEK3.1B bzw. SEK415.1M. Camurus Das EBIT des Unternehmens beträgt SEK537.7M, so dass der Zinsdeckungsgrad -13.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von SEK2.3B.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

SEK 0

Verschuldung

Zinsdeckungsgrad	-13.8x
Bargeld	SEK 2.27b
Eigenkapital	SEK 2.65b
Gesamtverbindlichkeiten	SEK 415.07m
Gesamtvermögen	SEK 3.06b

Jüngste Berichte zur Finanzlage

Recent updates

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Apr 19

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Feb 22

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Feb 17

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

Dec 20

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Apr 30

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Dec 09

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Sep 09

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: CAMXDie kurzfristigen Aktiva des Unternehmens (SEK2.8B) übersteigen seine kurzfristigen Passiva (SEK360.2M).

Langfristige Verbindlichkeiten: CAMXDie kurzfristigen Vermögenswerte des Unternehmens (SEK2.8B) übersteigen seine langfristigen Verbindlichkeiten (SEK54.9M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: CAMX ist schuldenfrei.

Schulden abbauen: CAMX hat in den letzten 5 Jahren keine Schulden gemacht.

Schuldendeckung: CAMX hat keine Schulden und muss daher nicht durch den operativen Cashflow gedeckt werden.

Zinsdeckung: CAMX hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Camurus Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Recent updates

Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study

Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly

Chief Technology Officer recently sold kr845k worth of stock

Consensus EPS estimates increase by 18%

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Consensus EPS estimates fall by 39%

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.2% to kr550

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

President exercised options to buy kr86m worth of stock.

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Price target increased by 16% to kr471

Investor sentiment improves as stock rises 20%

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to kr351

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Consensus EPS estimates increase by 21%

Consensus EPS estimates increase by 25%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Price target decreased by 7.3% to kr287

Third quarter 2022 earnings released: EPS: kr0.63 (vs kr0.11 loss in 3Q 2021)

Consensus EPS estimates increase by 17%

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Consensus forecasts updated

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Forecast to breakeven in 2022

Price target increased to kr305

Camurus AB (Publ) Provides Earnings Guidance for the Year 2022

Price target increased to kr283

Camurus AB (publ), Annual General Meeting, May 10, 2023

Camurus AB (publ) to Report Fiscal Year 2022 Final Results on Mar 30, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Vice President exercised options and sold kr178k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Elects Stefan Persson as New Board Member

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Full year 2021 earnings: EPS and revenues miss analyst expectations

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Camurus Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Pants with Genetic Obesity Disoisorder

Forecast breakeven date pushed back to 2022

Camurus AB Announces Braeburn Receives New Complete Response Letter for Brixadi in the US